期刊文献+

念珠菌的耐药机制及应对策略研究 被引量:15

下载PDF
导出
摘要 念珠菌是临床上深部真菌感染的主要致病菌,致死率高,耐药性严重,耐药机制主要包括:药物作用靶标结构变异;靶标表达增加;靶标缺失;影响药物外排;改变细胞膜甾醇成分;形成生物被膜;钙调神经磷酸酶通路激活等。针对真菌耐药性问题,首要的应对策略应是研究发现新的药靶,开发全新结构和作用方式的新药。同时,筛选研究能降低真菌耐药性的新药,通过与现有的抗真菌药物联合使用,也可作为临床克服真菌耐药,防治真菌感染的有效策略。
出处 《中国真菌学杂志》 2011年第4期193-198,共6页 Chinese Journal of Mycology
基金 国家高技术研究发展计划(863计划 2008AA02Z128) 上海市基础研究重点项目(08JC1405900)
  • 相关文献

参考文献7

  • 1Mukherjee PK, Chandra J, Kuhn DM, et al. Mechanism of azole resistance in Candida albicans biofilms: phase specific role of efflux pumps and membrane sterols [ J ]. Infect Immun, 2003, 71:4333-4340.
  • 2Gonzdlez IJ, Milewski S, Villag6mez CJC, et al. Sporothrix schenckii :purification and partial biochemical characterization of glucosamine4-phosphate synthase, a potential antifungal target[J]. Med Mycol,2010,48 ( 1 ) :110-121.
  • 3Warn PA, Sharp A, Morrissey G,et al. Activity of aminocandin ( IP960 ; HMR3270 ) compared with amphotericin B, itracon- azole, caspofungin and micafungin in neutropenic murine mod- els of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus [ J ]. Int J Anti- microb Agents,2010 ,35 (2) : 146-151.
  • 4Sandbaken MG, Lupisella JA, DiDomenico B, et al. Protein syn- thesis in yeast. Structural and functional analysis of the gene en- coding elongation factor 3 [ J ]. J Biol Chem, 1990,265 ( 26 ) : 15838-15844.
  • 5Nico D, Teresa TL, Katherine SB, et al. A gain-of-gunction mu- tation in the transcription factor Upc2p causes upregulation of er- gosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate [ J ]. Eukayotic Cell, 2008,7(7) :1180-1190.
  • 6王红,叶嗣颖.深部真菌感染临床特点分析[J].中国微生态学杂志,2010,22(8):734-735. 被引量:8
  • 7FENG Li-juan WAN Zhe WANG Xiao-hong LI Ruo-yu LIU Wei.Relationship between antifungal resistance of fluconazole resistant Candida albicans and mutations in ERG11 gene[J].Chinese Medical Journal,2010(5):544-548. 被引量:24

二级参考文献34

  • 1Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995; 35: 103-114.
  • 2Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
  • 3Vuffray A, Durussel C, Boerlin P, Boerlin-Petzold F, Bille J, Glanser ME et al. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS 1994; 8: 708-709.
  • 4Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 1998; 42: 241-253.
  • 5Marichal E Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W, et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999; 145: 2701-2713.
  • 6White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402.
  • 7National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. M27-A2. National Committee for Clinical Laboratory Standards, WAYNE, PA. 2002.
  • 8Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 1998 42: 3065-3072.
  • 9Loffler J, Kelly SL, Hebart H, Schumacher U, Lass-Florl C, Einsele H. Molecular analysis of cyp51 from fluconazole resistant Candida albicans strains. FEMS Microbiol Lett 1997; 151: 263-268.
  • 10Perea S, Lopez-Ribot JL, Santillan RA, Martinez M, mechanisms of resistance Kirkpatrick WR, McAtee RK, et al. Prevalence of molecular to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676-2684.

共引文献30

同被引文献396

引证文献15

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部